Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).

Yalon M, Rood B, MacDonald TJ, McCowage G, Kane R, Constantini S, Packer RJ.

Pediatr Blood Cancer. 2013 Jan;60(1):71-6. doi: 10.1002/pbc.24142. Epub 2012 Mar 20.

PMID:
22434731
2.

Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S.

J Clin Oncol. 2012 Apr 20;30(12):1358-63. doi: 10.1200/JCO.2011.34.5843. Epub 2012 Mar 5.

PMID:
22393086
3.
4.

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.

Pediatr Blood Cancer. 2013 May;60(5):776-82. doi: 10.1002/pbc.24297. Epub 2012 Sep 13.

PMID:
22976922
5.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

6.

Results of the treatment of children with recurrent gliomas with lomustine and vincristine.

Lefkowitz IB, Packer RJ, Sutton LN, Siegel KR, Bruce DA, Evans AE, Schut L.

Cancer. 1988 Mar 1;61(5):896-902.

7.
8.

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.

Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T.

J Neurooncol. 2012 Nov;110(2):245-50. doi: 10.1007/s11060-012-0960-y. Epub 2012 Aug 24.

9.

Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

Preusser M, Gelpi E, Rottenfusser A, Dieckmann K, Widhalm G, Dietrich W, Bertalanffy A, Prayer D, Hainfellner JA, Marosi C.

J Neurooncol. 2008 Sep;89(2):211-8. doi: 10.1007/s11060-008-9608-3. Epub 2008 May 6.

PMID:
18458820
10.

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.

Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC.

J Clin Oncol. 2008 Oct 20;26(30):4921-7. doi: 10.1200/JCO.2007.15.2306. Epub 2008 Sep 15.

11.

Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.

Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R.

J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81.

PMID:
11464982
12.

Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.

Lancaster DL, Hoddes JA, Michalski A.

J Neurooncol. 2003 Jul;63(3):289-94.

PMID:
12892235
14.

Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.

Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S.

Pediatr Blood Cancer. 2014 Jan;61(1):128-33. doi: 10.1002/pbc.24656. Epub 2013 Aug 17.

PMID:
23956145
15.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.

PMID:
18316689
16.

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY.

Neuro Oncol. 2007 Jul;9(3):354-63. Epub 2007 Apr 23.

17.

3D conformal radiotherapy and cisplatin for recurrent malignant glioma.

VanderSpek L, Fisher B, Bauman G, Macdonald D.

Can J Neurol Sci. 2008 Mar;35(1):57-64.

PMID:
18380278
18.

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK.

Neuro Oncol. 2006 Jan;8(1):67-78.

19.

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.

Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G.

J Neurooncol. 2011 Jul;103(3):673-80. doi: 10.1007/s11060-010-0444-x. Epub 2010 Nov 1. Erratum in: J Neurooncol. 2011 Jul;103(3):681.

PMID:
21038110
20.

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E; Princess Margaret Hospital Phase II Consortium.; National Cancer Institute of Canada Clinical Trials Group Study..

J Clin Oncol. 2007 Jun 1;25(16):2178-83.

PMID:
17538162

Supplemental Content

Support Center